| Abstract | BACKGROUND: Controlled clinical trials have shown efficacy of high-dose ciprofloxacin for hospital-acquired (HAP) or nosocomial pneumonia. But it has yet to be demonstrated whether this good efficacy also holds true for routine intensive-care patients outside of controlled trials. PATIENTS: In a post-marketing surveillance study at 87 intensive-care units in Germany we analyzed 676 cases of nosocomial pneumonia treated with intravenous ciprofloxacin in a daily dosage of at least 400 mg. RESULTS: 538 (80 %) patients were evaluable for efficacy. Cure or improvement was reported in 76 % of the cases. Clinical success rate was higher in previously untreated patients receiving ciprofloxacin as monotherapy (85.3 %) or in combination with other antibiotics (78.4 %) than in those who received ciprofloxacin as monotherapy (73.1 %) or as combination therapy (69.2 %) after an antibiotic pretreatment. In the 66 patients with Pseudomonas aeruginosa as causal pathogen, clinical success rate was 86.4 %. 32 adverse events classified as possibly or probably related to ciprofloxacin occurred in 3.1 % of patients; all of those were reversible. CONCLUSIONS: Due to the high success rate, even in cases with failed antimicrobial pretreatment, and the favourable risk-benefit ratio of high-dose ciprofloxacin, ciprofloxacin appears to be an attractive choice in the empiric treatment of hospital-acquired pneumonia. |
| Authors | S Kljucar, K L Rost, H Landen
(Affiliation: DRK-Kliniken Westend, Zentrale Abteilung für Anästhesiologie und Intensivmedizin, Berlin, Germany.)
|
| Journal | Pneumologie (Stuttgart, Germany)
(Pneumologie)
Vol. 56
Issue 10
Pg. 599-604
(Oct 2002)
ISSN: 0934-8387 Germany |
| Vernacular Title | Ciprofloxacin in der Therapie der nosokomialen Pneumonie: Eine Anwendungsbeobachtung bei 676 Patienten. |
| PMID | 12375221
(Publication Type: English Abstract, Journal Article, Multicenter Study)
|
| Chemical References |
- Anti-Infective Agents
- Ciprofloxacin
|
| Topics |
- Anti-Infective Agents
(administration & dosage, therapeutic use)
- Ciprofloxacin
(administration & dosage, therapeutic use)
- Cross Infection
(drug therapy)
- Drug Therapy, Combination
- Germany
- Humans
- Infusions, Intravenous
- Pneumonia
(drug therapy)
- Pseudomonas Infections
(drug therapy)
- Pseudomonas aeruginosa
|
